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P.T. PISCIOTTO
R E V I E W
Sick neonates are among the more heavily
transfused groups of patients in the hospital setting.1
Transfusion therapy for neonates began early in the 20th
century. One of the first controlled trials compared the
use of intravenous versus intramuscular administration
of whole blood in infants with hemorrhagic disease of
the newborn (vitamin K deficiency bleeding).2 The use
of plasma components in neonates for hemostatic
abnormalities coincided with the availability of these
blood components for all patients in the 1950s. In
general, plasma transfusions are administered less
frequently to neonates than RBC transfusions.3,4
Inasmuch as the physiologic state of the hemostatic
system in newborns is different compared with that in
older children and adults, it is important to have a good
understanding of the developmentally unique aspect of
this system to appreciate the therapeutic goals of plasma
replacement therapy.5 Although there are guidelines for
neonatal transfusion as well as recommendations to
assess transfusion criteria, most of these are derived
from consensus opinion because there are limited
evidence-based data from controlled clinical trials.6,7
Developmental Hemostasis
Normal hemostasis is the physiologic mechanism by
which the body controls bleeding and prevents
thrombotic events. This results from a dynamic balance
between the formation of thrombin, fibrin deposition,
thrombin inhibition, and fibrinolysis. The process can
be viewed in three overlapping stages, starting with the
formation of a platelet plug, which involves the
endothelial layer of the vessel wall and platelets,
followed by the interaction of platelets and plasma
procoagulant proteins (coagulation factors) to form a
stable fibrin clot limited to the area of vascular injury
(by action of anticoagulant proteins). The final stage
results in the breakdown of the fibrin clot and repair of
the vascular damage (fibrinolytic system).
Plasma coagulation proteins do not cross the
placenta. Synthesis of these proteins begins in the first
trimester of pregnancy. Although the basic coagulation,
anticoagulation, and fibrinolytic pathways are the same
in neonates as in older children and adults, the
concentration of many of the coagulation proteins
varies greatly. Concentrations are selectively and
significantly different and dependent on both the
gestational and postnatal age of the infant.5 Several
factors, including fibrinogen; factorsVIII,V,and XIII; and
vonWillebrand factor, achieve adult levels at birth, but
most other hemostatic proteins are decreased. The
altered state is the result of multiple mechanisms
including decreased production as a result of the
immature nature of the neonatal liver, increased
clearance of the proteins, consumption at the time of
birth, and synthesis of proteins that have decreased
functional activity.5 In full-term infants these factors are
approximately 50 percent of adult levels and even lower
in healthy premature infants.8,9 As a result of the
decreased production of these factors, the generation of
thrombin,which is the key enzyme in the formation of
fibrin, may be decreased or delayed.10 Despite these
findings, healthy infants are hemostatically stable. The
standard laboratory tests of coagulation function,
however—the prothrombin time and activated partial
thromboplastin time—are greater than the adult
reference ranges, reflecting the reduction of these
multiple procoagulant proteins. Therefore, it is impor-
tant to refer to established reference ranges for age
when evaluating hemostatic integrity and potential need
for transfusion in the neonate. The newborn hemostatic
system matures rapidly, with variables reaching adult
levels usually by 6 months. This process is accelerated
in premature infants, who show similar levels of
coagulation proteins to term infants by 6 months after
birth. As this is a dynamic maturing system multiple
reference ranges,reflecting the gestational and postnatal
age of the infant, are necessary. The ranges published
byAndrew et al.5 are the most comprehensive and often
are used as guidelines.11 It is important to remember,
however, that these ranges were established using
different reagents and assay systems for measuring
coagulation function than are available today.
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The plasma concentration of the anticoagulants,
which include anti-thrombin III;heparin cofactor II;and
the vitamin K–dependent factors,protein C and protein
S,are also decreased. This appears to be compensated in
part by the enhanced thrombin inhibition via the
increased levels of α2-macroglobulin (α2-M). In terms of
the fibrinolytic system in the newborn there is a
decrease in the concentration of plasminogen and
therefore the generation of plasmin, which is the key
enzyme responsible for breakdown of fibrin.5 Despite
these developmental differences,the hemostatic system
in the healthy infant is largely physiologic, providing
protection from both bleeding and thrombosis because
the balance between procoagulants,anticoagulants,and
the fibrinolytic system is maintained. The concern,
however, is that there is very little reserve capacity and
any additional pathologic insult, such as birth asphyxia,
which is associated with disseminated intravascular
coagulation (DIC) in the neonate, may contribute to
morbidity in the sick and premature infant.
Bleeding in the Neonatal Period
Bleeding complications from coagulation abnormal-
ities in the newborn are usually the result of an acquired
defect in hemostasis,although congenital disorders may
be present,particularly in association with an iatrogenic
challenge.11 The clinical presentation of bleeding in the
neonate may present at various sites, and the conse-
quences are different compared with those of older
children and adults. Oozing from the umbilicus or
peripheral blood sampling sites,bleeding into the scalp
resulting in large cephalohematomas, or bleeding from
circumcision are some of the typical ways bleeding may
present in the neonate. Often,however, the first sign is
an intracranial hemorrhage (ICH), and even a minor
bleed can result in shock.
Disseminated Intravascular Coagulation
The incidence of DIC is high in the neonate,
particularly the premature infant. DIC is an acquired
coagulation disorder in which both the coagulation and
fibrinolytic systems are activated, resulting in the
formation of microthrombi and a bleeding tendency
owing to the consumption of certain coagulation
factors. This occurs as a secondary event to another
disease entity. In the neonate this can include many
conditions such as sepsis, birth asphyxia, acidosis,
respiratory distress syndrome (RDS), necrotizing
enterocolitis, infection, and shock.12 Because these
infants are already starting with lower levels of
procoagulant proteins, the increased consumption of
these proteins, in conjunction with consumption of
platelets,can result in a profound coagulopathy early in
the disease process. The clinical spectrum of DIC in the
neonate can range from an asymptomatic low-grade
compensated DIC to fulminant DIC characterized by
bleeding requiring replacement therapy. Although there
are no randomized studies looking at the efficacy of
replacement therapy for bleeding associated with DIC,
its use in this clinical situation is generally recom-
mended in guideline documents.6,7,11 The latter may
necessitate not only replacement of procoagulant
proteins and naturally occurring inhibitors with plasma
transfusion but also platelet transfusions. Cryoprecip-
itate, which contains a higher concentration of factor
VIII and fibrinogen per unit volume of FFP, may be
particularly useful in the presence of hypofibrino-
genemia. There has been some evidence of beneficial
effects with the use of antithrombin and protein C
concentrates in adults with DIC associated with
multiorgan failure.13 There has been limited clinical
experience with their use in neonates, and therefore
further clinical trials would be warranted for definitive
recommendation regarding their use as treatment. It is
important to remember,however, that if the underlying
condition is not corrected the hemostatic improvement
will only be temporary. Therefore one of the most
important aspects of managing DIC is taking aggressive
measures to reverse the underlying disease process.
Vitamin K Deficiency
Hemorrhagic disease of the newborn was described
in 1894,14 but was not linked to vitamin K deficiency
until the mid-1900s. The vitamin K–dependent factors
as mentioned previously are physiologically low at birth
and functionally inactive in the presence of vitamin K
deficiency. Vitamin K is required for modifying the
coagulation proteins II, VII, IX, and X and the
anticoagulant proteins C and S. Placental transfer of the
vitamin is poor, and neonates have limited stores of
vitamin K at birth. Because intestinal bacteria produce
vitamin K2,a contributing factor for decreased vitamin K
in neonates may be the presence of a sterile gut in the
first few days of life. This can be further aggravated in
infants who are breast-fed,because vitamin K content is
also limited in breast milk. In most countries prophy-
lactic vitamin K1 (phytonadione, which is present in
green leafy vegetables) is given after birth to reduce the
risk of hemorrhagic disease. There are actually three
classifications of hemorrhagic disease of the newborn,
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which are based on the clinical presentation and risk
factors.15 Early hemorrhagic disease is the rarest, with
the onset of bleeding occurring within the first 24
hours. Bleeding is variable,but can be serious, including
ICH. Early onset is usually associated with medications,
such as anticonvulsants, taken during pregnancy that
can cross the placenta and interfere with vitamin K
metabolism.16 In an attempt to reduce early hemor-
rhagic disease, strategies for the prophylactic use of
antenatal vitamin K have been suggested.17 Classic
hemorrhagic disease of the newborn presents between
2 and 5 days of life with purpura, mucosal membrane
bleeding, bleeding from the umbilicus, or gastro-
intestinal bleeding in an infant who otherwise appears
well. Presentation with ICH appears to be relatively less
common. The classic form of hemorrhagic disease is
usually associated with infants who are being breast-fed,
but may also occur if there are feeding problems. A late
form of hemorrhagic disease may also occur in the
newborn, in which the onset of bleeding occurs after
the first week of life,peaking between 2 and 8 weeks of
life. Although breast-feeding and inadequate prophylaxis
with vitamin K are frequently documented, there are a
variety of diseases that can compromise the supply of
vitamin K that must be considered. Unlike those with
classic hemorrhagic disease of the newborn, these
infants often present with ICH,which can be associated
with significant morbidity (neurologic) and mortality.
The treatment of vitamin K deficiency will be dictated
by the clinical situation. The vitamin K–dependent
proteins increase within a few hours after the
administration of a parenteral dose of vitamin K. In the
presence of significant bleeding that may be life
threatening, plasma in addition to vitamin K can be
given to correct the hemostatic defect.6,7,11
Liver Disease
Although some degree of hepatic impairment is not
uncommon in the neonatal period and may occur in
conjunction with sepsis, hypoxia, and total parenteral
nutrition, fulminant hepatic failure is an uncommon
event. Viral infections, metabolic disorders, storage
disorder, and shock are some recognized causes of
neonatal hepatic failure.18 The coagulopathy of liver
failure is the result of several processes, but reduced
synthesis of procoagulant proteins plays an important
role in a setting in which there already are physio-
logically reduced levels of many coagulation proteins.
Other contributing factors are decreased clearance of
activated coagulation factors by the liver, activation of
fibrinolysis, impaired utilization of vitamin K, and
thrombocytopenia. In the presence of clinical bleeding
some temporary benefit may be achieved by the
replacement of coagulation proteins with plasma and
cryoprecipitate. Management of the coagulopathy,
however,would essentially be supportive until recovery
of hepatic function could be achieved. If there is
evidence of cholestasis, the administration of vitamin K




A substantial coagulopathy occurs during cardio-
pulmonary bypass (CPB), which is the result of several
different contributing factors. Neonates are at higher risk
for increased bleeding, related in part to the immature
nature of their coagulation system. In addition the often
complex repairs that are needed can require longer CPB
time or deeper hypothermia.19–22 Hypothermia (a means
of cerebral protection), which is often induced during
CPB,can alter hemostasis by negatively affecting platelet
function as well as inhibiting serine protease activity.
During CPB a hemodilution occurs, which is more
pronounced in the neonate than in larger pediatric and
adult patients. This is the result of the small intravascular
volume of the neonate relative to the volume of the
bypass circuit. After the onset of CPB mean plasma
concentrations of procoagulant proteins and inhibitors
are reduced by approximately 50 percent of pre-CPB
values.19 There is a similar reduction in the fibrinolytic
proteins. All of these changes have a significant effect on
the generation of thrombin. In addition to the hemo-
dilution, and despite systemic heparinization, there is
evidence that both the coagulation and fibrinolytic
systems are activated by the CPB circuit, which may
result in a low-grade consumptive coagulopathy. A
dilutional thrombocytopenia also occurs, and platelet
function is impaired. Various strategies have been used
to decrease the morbidity of CPB and transfusion
requirements. Some of these have included minimizing
the amount of exposure to the CPB circuit by keeping
the duration of CPB as short as possible and minia-
turizing the circuit to limit the artificial surface area to
which the blood is exposed.21,22 This miniaturization
also results in smaller priming volumes and less
hemodilution. The use of ultrafiltration during or imme-
diately after CPB to remove excess fluid has helped to
maintain the patient’s hemoglobin through hemocon-
centration, attenuate the dilutional coagulopathy, and
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reduce postoperative bleeding.22,23 The use of aprotinin,
which is a serine protease inhibitor used to prevent
fibrinolysis as well as contact activation, has not shown
consistent results in the pediatric setting and warrants
further investigation as to its risk-benefit ratio.21 A recent
prospective randomized controlled trial in 200 infants
less than 1 year of age compared the use of fresh whole
blood (less than 48 hours) with reconstituted blood
consisting of one unit of RBCs in additive solution and
one unit of thawed FFP for priming the bypass circuit
and for adding to the bypass circuit when the patients
were rewarmed at the end of surgery.24 Fresh whole
blood did not confer a clinical or biochemical advantage
over reconstituted blood. However, an increased length
of stay in the intensive care unit and increased peri-
operative fluid overload were associated with priming
the circuit with fresh whole blood.
Extracorporeal membrane oxygenation (ECMO) is a
modified heart-lung machine, which provides gas
exchange to support patients who have severe but
potentially reversible respiratory or cardiac failure.
Some of the differences from patients requiring CPB are
that these patients are maintained at normal body
temperature, undergo extrathoracic cannulation from
relatively accessible vessels, and because there is no
large venous reservoir in the circuit, require only partial
anticoagulation with heparin.25 The time course for
ECMO support,however,can be days to weeks. As with
CPB, coagulation complications of ECMO can be
significant as the patient is heparinized, and the
associated activation and consumption of procoagulant
factors and platelets related to the exposure of blood to
artificial surfaces is also present. If ECMO is initiated
after open heart surgery, the coagulation effects are
additive. The number of transfusions required varies
considerably based on individual patient characteristics
as well as variation related to the institutional protocol
and ECMO technique. There have been no clinical trials
looking at the influence of transfusion protocols on
clinical outcome. Approximately 15 percent of neonates
on ECMO sustain an ICH.25
Intracranial Hemorrhage
The commonest form of ICH in the premature infant
is a periventricular-intraventricular hemorrhage (IVH).
The incidence is around 15 to 20 percent for infants less
than 32 weeks’ gestation.26 The majority occur within
the first 72 hours of life. Although low birth weight and
increasing prematurity are associated with IVH,
additional risk factors are RDS, intrapartum asphyxia,
and vaginal delivery. The etiology is incompletely
understood. Some of the factors believed to contribute
to IVH include alterations in cerebral blood flow,fragility
of the immature germinal matrix vessels, and hypoxia-
induced endothelial damage. These appear to be more
significant than impaired hemostasis. A randomized
control trial of prophylactic FFP carried out in the 1980s
did show a reduced risk of IVH documented by cranial
ultrasound.27 However,there was no substantial change
in the coagulation profile after the administration of FFP,
which suggested that the benefit seen might have been
secondary to circulatory stabilization after volume
expansion. A subsequent large prospective randomized
control study undertaken by the Northern Neonatal
Nursing Initiative Trial Group, comparing the infusion
of FFP, gelatin, or glucose in 776 preterm infants less
than 32 weeks’gestation within 2 hours of birth,showed
no evidence that any of the interventions had any effect
on death or disability, followed out 2 years.28,29 Current
evidence therefore does not support the routine use of
prophylactic FFP in preterm infants at risk for IVH.7
Indications and Contraindications
FFP has been transfused to neonates for a variety of
reasons that may not have had any proven benefit.
National surveys of transfusion practice have shown that
although neonates receive relatively few FFP transfusions
as compared with RBC transfusions, a percentage of
hospitals responded that some of the frequent uses of
FFP were either to treat hypovolemia, as fluid replace-
ment during partial exchange transfusion,or as adjuvant
therapy for sepsis.3,4 Hypovolemia as the most frequent
indication for transfusion of plasma was reported by 11
percent of respondents in one survey and 41 percent in
another. These surveys reflect practice in the late 1980s
and early 1990s. There have been no recent surveys to
determine whether there has been a shift in transfusion
practice. A more recent report of transfusion practice in
a single institution showed that a significant shift
toward appropriate use of plasma occurred only after
implementation of a computer-based audit system that
included an educational component as follow-up.30
Before the initiation of the audit system approximately 8
percent of the plasma transfusions administered to
neonates would have been classified as not being
appropriate because there was no evidence of a
coagulopathy. This was reduced to approximately 1
percent after an educational effort.
The underlying principle that should govern the
appropriateness of plasma transfusion in the neonate is
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the same as that in older patients: plasma transfusion
should be given for the treatment of clinically significant
bleeding, or to prevent bleeding before an invasive
procedure, when there is a decrease in one or more
coagulation factors, and a safer more appropriate
alternative to treatment does not exist.6,7 Some of the
difficulty in the neonate is trying to determine what role
an immature hemostatic system plays in the etiology of
a bleed. This is the case with IVH in which randomized
clinical trials have been helpful.
Plasma Components
There are several plasma components available that
are used for coagulation factor replacement. Plasma
from whole blood collected in either CPDA-1, CPD, or
CP2D that is separated by centrifugation and frozen
within 8 hours is labeled as FFP and if frozen within 24
hours as “Plasma Frozen Within 24 Hours After Phle-
botomy” (FP24). Frozen plasma is thawed usually in a
water bath and should be either transfused immediately
or stored at 1 to 6°C for up to 24 hours. If these frozen
products are thawed and not used within 24 hours they
are relabeled as “Thawed Plasma” and need to be
transfused within 5 days. The processing of FP24 may
result in slightly lower concentration of factors V and
VIII. However, based on in vitro data of the functional
activity of these factors, they still are within the normal
reference ranges, supporting the use of these products
for the accepted indications for plasma transfusion.31–33
The concentrations of coagulation factors in thawed
plasma from FFP which is stored at 1 to 6°C until
expiration (day 5) are stable with the exception of
factor VIII activity, which is reduced by 35 to 41
percent.34 FFP can also be collected by apheresis
technology. In this case the anticoagulant is eitherACD
or sodium citrate,and the plasma is frozen within 6 to 8
hours.
Dose and Administration
No specific compatibility testing is required before
transfusion of frozen plasma components. However,
because plasma contains isohemagglutinins, the com-
ponent must be ABO compatible with the recipient’s
RBCs. Hemolytic reactions attributable to incompatible
plasma transfusions have been reported in the
neonate.35 If the recipient’s ABO type is not available,
then group AB plasma can be administered. Because
Rh-alloimmunization rarely occurs as a result of Rh(D)
mismatch of frozen plasma components,Rh(D) compat-
ibility is not essential. After the frozen plasma is thawed,
aliquots can be prepared using a sterile connecting
device and transfer bags if multiple doses are needed.
A guide for replacement therapy is to achieve a
“minimal hemostatic level” based on gestational and
postnatal age of the infant.36 There have been no studies
looking at the recovery of coagulation factors or clear-
ance time after FFP administration in a sick neonate.
A common dosing regimen has been 10 to 20 mL/kg.
This theoretically should result in a rise in coagulation
factors of approximately 20 percent immediately after
infusion.The dose and frequency,however,will depend
on the clinical situation and plasma concentration that
is being targeted. Posttransfusion monitoring of the
coagulation status is important to determine optimal
therapy.
Summary
Although there has been an overall trend toward
reduction of transfusions in neonates, limited data from
randomized clinical trials to guide practice exist. The
neonatal hemostatic system is immature at birth,placing
sick premature infants, who may have minimal reserve
capacity, at potential increased risk for bleeding
complications. In general, there is agreement that
plasma should be transfused to correct deficiencies in
the face of bleeding. What is needed,however, is a better
understanding of when these deficiencies do or do not
affect bleeding risk and outcome to further provide
more evidence-based approaches to transfusion
practice.
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